Welcome to chemicalbook!
400-158-6606
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

ChemicalBook > Product Catalogue >Biochemical Engineering >Inhibitors >Proteases >HCV Protease Inhibitors >Telaprevir

Telaprevir

Telaprevir Structure
  • ₹6007.88 - ₹24345.43
  • Product name: Telaprevir
  • CAS: 402957-28-2
  • MF: C36H53N7O6
  • MW: 679.85
  • EINECS:609-814-6
  • MDL Number:MFCD11616089
  • Synonyms:(1S,3aR,6aS)-2-((S)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxaMido)acetaMido)-3,3-diMethylbutanoyl)-N-((S)-1-(cyclopropylaMino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxaMide;Cyclopenta(c)pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-((1S)-1-((cyclopropylamino)oxoacetyl)butyl)octahydro-, (1S,3aR,6aS)-;VX-950;VX-950 (Teleprevir);(1S,3aR,6aS)-(2S)-2-Cyclohexyl-N-(pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-((1S)-1-((cyclopropylamino)oxoacetyl)butyl)octahydrocyclopenta[c]pyrrole-1-carboxamide;Telaprevir;(1S,3aR,6aS)-2-((S)-2-((S)-2-cyclohexyl-2-(pyrazine-6-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)-octahydrocyclopenta[c]pyrrole-1-carboxamide VX-950;TELAPREVIR; VX-950
2 prices
Selected condition:

Brand

  • Sigma-Aldrich(India)

Package

  • 5MG
  • 25MG
  • ManufacturerSigma-Aldrich(India)
  • Product numberSML2654
  • Product descriptionTelaprevir ≥90% (HPLC)
  • Packaging5MG
  • Price₹6007.88
  • Updated2022-06-14
  • Buy
  • ManufacturerSigma-Aldrich(India)
  • Product numberSML2654
  • Product descriptionTelaprevir ≥90% (HPLC)
  • Packaging25MG
  • Price₹24345.43
  • Updated2022-06-14
  • Buy
Manufacturer Product number Product description Packaging Price Updated Buy
Sigma-Aldrich(India) SML2654 Telaprevir ≥90% (HPLC) 5MG ₹6007.88 2022-06-14 Buy
Sigma-Aldrich(India) SML2654 Telaprevir ≥90% (HPLC) 25MG ₹24345.43 2022-06-14 Buy

Properties

Melting point :116-123°C
Density :1.25
storage temp. :Sealed in dry,Store in freezer, under -20°C
solubility :Chloroform, Methanol (Slightly)
pka :11.84±0.20(Predicted)
form :Solid
color :Pale Yellow to Light Yellow

Safety Information

Symbol(GHS): GHS hazard pictograms
Signal word: Warning
Hazard statements:
Code Hazard statements Hazard class Category Signal word Pictogram P-Codes
Precautionary statements:
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P280 Wear protective gloves/protective clothing/eye protection/face protection.
P308+P313 IF exposed or concerned: Get medical advice/attention.
P405 Store locked up.
P501 Dispose of contents/container to..…

Description

The hepatitis C virus (HCV) protease inhibitor telaprevir (VX-950, MP- 424,LY-570310) was approved by the U.S. FDA in May 2011 for the treatment of genotype 1 chronic HCV infection in adult patients in combination with peginterferon alfa and ribavirin (PR). Telaprevir and boceprevir (vide supra) are the first two HCV protease inhibitors to be approved for treatment of HCV infection. Telaprevir is a HCV NS3-4A protease inhibitor that exerts its antiviral effect by blocking the release of nonstructural viral proteins from a polyprotein precursor. Telaprevir is a potent inhibitor of the protease (IC50=10 nM) and is active in cell culture (HCV 1b replicon assay, EC50=354 nM). Telaprevir was identified from efforts to truncate a decamer peptide inhibitor derived from the natural substrate NS5A-5B and was guided by structure-based design. The ketoamide group of telaprevir forms a covalent, reversible bond with the active site serine hydroxyl of the protease and compensates for the loss of affinity resulting from truncation of the peptide. Despite the presence of the reactive keto-amide group, telaprevir is >500-fold less potent against other serine proteases. Synthesis of the key octahydrocyclopenta[c]pyrrole-1-carboxylic acid fragment of telaprevir is achieved by a-deprotonation of Boc-protected 3-azabicyclo[3.3.0]nonane followed by reaction with CO2 and resolution of the racemic acid. Alternatively, deprotonation is carried out in the presence of a chiral amine to give the enantiomerically enriched acid.

Related product price